You are here

JNJ

J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant

J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant

Yahoo/Zacks.com

non-small cell lung cancer

Flag link:

Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?

Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?

Motley Fool

Intuitive Surgical

robotic surgery

Flag link:

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff

Fierce Biotech

Propella Therapeutics

prostate cancer

Flag link:

J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses

J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses

Fierce Pharma

peripheral artery disease

Flag link:

Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis

Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis

Biopharma Reporter

rheumatoid arthritis

clinical trials

Flag link:

J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina

J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina

Fierce Pharma

Fujifilm Diosynth Biotechnologies

Flag link:

J&J targets 2024 for Ottava FDA filing

J&J targets 2024 for Ottava FDA filing

Medtech Dive

robotic surgery

Flag link:

HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations

HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations

BioSpace

Inflation Reduction Act

Flag link:

Study of Johnson & Johnson device shows promising results for AFib

Study of Johnson & Johnson device shows promising results for AFib

Clinical Trials Arena

atrial fibrillation

Flag link:

Amgen scores FDA approval for Stelara biosimilar

Amgen scores FDA approval for Stelara biosimilar

Pharmaceutical Technology

Flag link:

GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy

GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy

Reuters

Flag link:

Cidara’s J&J-partnered immunotherapy could target flu and cancer

Cidara’s J&J-partnered immunotherapy could target flu and cancer

Pharma Voice

drug-Fc conjugates

Flag link:

Janssen reports data from Phase III trial of lung cancer drug

Janssen reports data from Phase III trial of lung cancer drug

Clinical Trials Arena

clinical trials

non-small cell lung cancer

Flag link:

J&J bites back against dengue, linking antiviral to protection from infection in challenge trial

J&J bites back against dengue, linking antiviral to protection from infection in challenge trial

Fierce Biotech

Flag link:

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

OBR Oncology

non-small cell lung cancer

Flag link:

Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?

Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?

Medical Marketing and Media

EGFR-mutated NSCLC

Flag link:

After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti

After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti

Fierce Pharma

Multiple Myeloma

Flag link:

Why Johnson & Johnson Stock Flopped Today

Why Johnson & Johnson Stock Flopped Today

Motley Fool

Flag link:

J&J Signals Exit from Less Profitable Orthopedic Markets

J&J Signals Exit from Less Profitable Orthopedic Markets

Medical Devices and Diagnostics Industry

Flag link:

J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance

J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance

BioSpace

Flag link:

Pages